Precision Medicine

The explosion of genetic and molecular medicine has produced mountains of options and evidence. Conversely, there is often an alarming lack of evidence. This is where we come in.

We help you manage the flood of tests and drugs that emerge in this category daily. Accessed through the Hayes Knowledge Center, our comprehensive Precision Medicine solution focuses on thousands of genetic, genomic, and molecular diagnostic tests and precision medicine therapies addressing the questions our clients most frequently ask:

  • Will testing change patient management for this indication?
  • If so, what tests and/or therapies should I use?
  • Should we cover testing and/or therapies?
  • Can we manage these services internally?

 

 

Genetic Testing for Fragile X Syndrome

This report evaluates the clinical utility of fragile X syndrome (FXS) genetic testing. The evidence is considered for use of genetic testing to diagnose individuals with suspected disease; carrier testing for women with and without a family history of intellectual disability (ID), developmental delay, autism spectrum disorder (ASD), and FXS; prenatal testing for at-risk pregnancies; and newbo…

Next-Generation Sequencing (NGS) for Antimicrobial Resistance Profiling of Pathogens in Infections

The morbidity and mortality associated with chronic and acute infections are substantial, and antimicrobial-resistant pathogens are a global threat. Although there are numerous methods that can be used to evaluate the resistance profile of these pathogens, these methods are often time-consuming, may be inaccurate, and/or fail to provide sufficient information for the clinical management of ind…

Genetic Testing for PTEN Hamartoma Tumor Syndrome (PHTS)

This report examines the clinical utility of PTEN genetic testing of patients at risk for, or diagnosed with, PTEN hamartoma tumor syndrome (PHTS) based upon clinical symptoms, with or without a family history suggestive of PHTS. The goal of this report is to assess how genetic testing of patients meeting this criteria changes patient management, informs tre…

Genetic Testing for Hereditary Hemorrhagic Telangiectasia

This report examines the clinical utility of genetic testing for hereditary hemorrhagic telangiectasia (HHT) in pediatric and adult patients who are symptomatic for HHT and/or have a family history of HHT. The evidence for the use of genetic testing is evaluated in symptomatic and asymptomatic individuals wi…

The Clinical Utility of Genetic Testing for Hereditary Breast and Ovarian Cancer in Patients with a Personal History of Breast and/or Ovarian Cancer and a Suggestive Family History

This report examines the clinical utility of genetic testing for germline variants in patients with a personal history of breast and/or ovarian cancer and a family history suggestive of hereditary breast and ovarian cancer (HBOC). This report provides an assessment of the evidence for the use of genetic testing in this patient population. The goal of the report is to assess ho…

AlloMap (CareDx)

Heart transplantation is a widely accepted therapy for the treatment of end-stage cardiac disease. Approximately 20,000 people in the United States now live with a transplanted heart. Survival is nearly 90% at 1 year, 74.0% at 5 years, and the median survival is more than 10 years. Although long-term outcomes of cardiac transplantations have steadily improved, numerous life-threatening complic…